Matrix metalloproteinase-1, -3, and -9 gene polymorphisms and the risk of idiopathic dilated cardiomyopathy in a Chinese Han population

Clinical Biochemistry

Volumn 40, Issue 18, 2007, Pages 1427-1430

  Tang, Li jiang ^a   Chen, Xiao feng ^a   Zhu, Min ^a   Jiang, Jian jun ^a   Lu, Xian ben ^a   Du, Yu xi ^a   Wang, Bin ^a   Fang, Chong feng ^a   Xue, Yin sheng ^a   Shen, Wei feng ^b  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Idiopathic dilated cardiomyopathy (IDCM); Matrix metalloproteinase 1, 3, 9 (MMP 1, 3, 9); Polymerase chain reaction (PCR); Restriction fragment length polymorphism (RFLP); Single nucleotide polymorphism (SNP)

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE B; INTERSTITIAL COLLAGENASE; STROMELYSIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; AGED; CARDIOMYOPATHY, DILATED; CASE-CONTROL STUDIES; CHINA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, GENETIC; POPULATION GROUPS; RISK FACTORS;

EID: 36348978179     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2007.09.013     Document Type: Article

References (10)

1. Richardson P., McKenna W., Bristow M., Maisch B., Mautner B., O'Connell J., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathy. Circulation 93 (1996) 841-842
2. Spinale F., Coker M., Thomas C., Walker J., Mukherjee R., and Hebbar L. Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82 (1998) 482-495
3. Spinale F., Coker M., Heung L., Bond B., Gunasinghe H., Etoh T., et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102 (2000) 1944-1949
4. Mori S., Gibson G., and Mctiernan C. Differential expression of MMPs and TIMPs in moderate and severe heart failure in a transgenic model. J Card Fail 12 (2006) 314-325
5. Tziakas D., Chalikias G., Papaioakeim M., Hatzinikolaou E., Stakos D., Tentes I., et al. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol 96 (2005) 1449-1451
6. Schwartzkopff B., Fassbach M., Pelzer B., Brehm M., and Strauer B.E. Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4 (2002) 439-444
7. Gerad-Mizon F., de Groote P., Lamblin N., Hermant X., Dallongeville J., Amouyel P., et al. Prognostic impact of matrix metalloproteinase gene polymorphism in patients with heart failure according to the etiology of left ventricular systolic dysfunction. Eur Heart J 25 (2004) 688-693
8. Fang S., Jin X., Wang R., Li Y., Guo W., Wang N., et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 26 (2005) 481-486
9. Wagner S., Kluge B., Koziol J., Grau A., and Grond-Ginsbach C. MMP-9 polymorphisms are not associated with spontaneous cervical artery dissection. Stroke 35 (2004) e62
10. Diagnostic standard of Keshan disease. Chin J Endemiol 15 (1996) 367-376